search
Back to results

Circumferential Versus Ganglionated Plexi Ablation for Atrial Fibrillation (AF)

Primary Purpose

Atrial Fibrillation

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
GP ablation
PV isolation
Sponsored by
Cardiovascular Research Society, Greece
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atrial Fibrillation focused on measuring atrial fibrillation, PV isolation, ablation, ganglionic plexi, parasympathetic denervation

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • paroxysmal AF
  • age < 75 years
  • left atrial size < 5 cm

Exclusion Criteria:

  • malignancies
  • LVEF < 35%

Sites / Locations

  • Athens Euroclinic
  • State Research Institute of Circulation Pathology

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

1

2

3

Arm Description

Circumferential PV isolation

HF stimulation-guided and anatomic ablation of the main right and left atrial GP.

HF stimulation-guided and anatomic ablation of the main right and left atrial GP followed by circumferential PV isolation

Outcomes

Primary Outcome Measures

Freedom of AF or other atrial arrhythmia

Secondary Outcome Measures

Quality of life

Full Information

First Posted
April 30, 2008
Last Updated
April 10, 2013
Sponsor
Cardiovascular Research Society, Greece
search

1. Study Identification

Unique Protocol Identification Number
NCT00671905
Brief Title
Circumferential Versus Ganglionated Plexi Ablation for Atrial Fibrillation (AF)
Official Title
Circumferential vs Ganglionated Plexi Ablation in Patients With Paroxysmal Atrial Fibrillation: A Randomized Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2013
Overall Recruitment Status
Completed
Study Start Date
May 2008 (undefined)
Primary Completion Date
May 2011 (Actual)
Study Completion Date
August 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cardiovascular Research Society, Greece

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators have recently shown that anatomic ganglionated plexi (GP) ablation is inferior to circumferential pulmonary vein (PV) ablation for the treatment of paroxysmal AF. In this study, however, 26% of patients subjected to GP ablation alone without circumferential lesions were free of AF-recurrence up to one year after the ablation procedure. The investigators hypothesized that a combination of circumferential ablation with high-frequency-stimulation-identified GP ablation is superior to conventional circumferential ablation for the prevention of recurrences of paroxysmal atrial fibrillation (AF). The investigators are, therefore, conducting a randomized study comparing conventional circumferential ablation to a combination of circumferential ablation plus specific right and left atrial GP ablation in patients with drug-refractory paroxysmal AF.
Detailed Description
Introduction: In clinical studies, epicardial or endocardial partial ganglionated plexi (GP) ablation may prevent AF,1-4 and parasympathetic denervation has been proposed as a potential mechanism of circumferential or antral pulmonary vein (PV) ablation for the treatment of atrial fibrillation.5,6 However, there have also been reports of a temporary only 7 or even proarrhythmic effect of this approach by means of increased vulnerability of vagally-mediated AF,8,9 or ablation-related macro-reentrant left atrial tachycardias.10 Thus, the potential contribution of GP modification to clinical success of circumferential or antral pulmonary vein ablation that unavoidably affects adjacent GP is not known. Few publications exist on isolated GP ablation with variable results in terms of eliminating paroxysmal or persistent AF.11-13 We have recently shown that anatomically-oriented regional ablation at the areas of GP is superior to selective GP ablation, following identification of GP by high-frequency stimulation, conferring success rates comparable to these of pulmonary vein (PV) isolation procedures.13 We hypothesized that GP ablation guided by both HF stimulation and anatomical orientation is superior to PV isolation in patients with paroxysmal AF. We also aimed at comparing these two approaches with a combination of GP ablation and PV isolation. We are, therefore, conducting a randomized study comparing the three techniques in patients with drug-refractory paroxysmal AF. Methods: Patients with symptomatic, paroxysmal AF were randomized to three groups: Group 1. Patients are subjected to conventional PV isolation through circumferential ablation 1-2 cm from the PV ostium. Group 2. Patients are subjected to specific, HF stimulation-guided and anatomic ablation of the main right and left atrial GP. Group 3. Patients are subjected to specific, HF stimulation-guided and anatomic ablation of the main right and left atrial GP followed by PV isolation. Group 1. PV isolation. Circumferential ablation around the antra of the PV with the aid of electroanatomical mapping (Carto, Biosence-Webster) at a distance of approximately 1-2 cm from the ostia of the left and right PVs (46°C, 35W, 17 mL/min, Stockert, Biosense Webster), aimed at a voltage reduction by > 80% or a peak to peak bipolar electrogram <0.1 mV. End-point of both approaches is verification of PV isolation with demonstration of entry and exit block. The area encircled by circumferential ablation will be calculated using the software provided by the CARTO system. Group 2. GP ablation. The anatomic areas of GP are identified in the right and left atrium. Anatomic locations of GP were considered around the PV: anterior right (ARGP), inferior right (IRGP), left superior (LSGP), and left inferior GP (LIGP). In addition the following GP were considered: The GP at the crux of the left atrium which is probably near or in continuation with the IRGP (2-3 cm below the lower edge of RIPV), expanding both toward the mitral annulus and inferior aspect of the LA posterior wall (cruxGP). This GP was also approached from the crux of the RA, behind the tendon of Tadaro/Eustachian ridge and the coronary sinus ostium. The GP at the septal-posterior aspect of the junction of the RA with the SVC (this GP may actually correspond to the 3rd fat pad located at the junction of SVC-RA-right PA-aorta).14-18 Following anatomic orientation, precise determination of the location of parasympathetic GP is accomplished by high-frequency stimulation.19 Patients are deeply sedated with diamorphine and diazepam without intubation, and high-frequency stimulation is delivered with a Grass stimulator at 1,200 bpm (20 Hz) with a pulse width of 10 ms at 20 V. A predominant parasympathetic response is defined as induction of AV block (> 2 sec) and hypotension or prolongation of the R-R interval by >50% during AF, following a 5 seconds application of high-frequency stimulation.19 Before applying high-frequency stimulation to inferior GP, extra care is taken to ensure that the catheter tip is not on the annulus to avoid induction of ventricular fibrillation. Verification of catheter position is accomplished by examination of recorded electrograms and anatomic location on both lateral views on CARTO. The sequence of GP ablation is: LS GP, LI GP, ARGP GP, IRGP, right anterior GP and the crux GP situated in the RA. After each ablation lesion (46°C, 35W for 60 seconds, 17 mL/min), parasympathetic response is reassessed by high-frequency stimulation. End-point for radiofrequency delivery is abolition of parasympathetic response. Following specific GP ablation, anatomical ablation is performed as previously described, in a way that the designated anatomic areas of GP are ablated. Group 3. GP ablation and PV isolation. Following specific and anatomic GP ablation as previously described, PV isolation is accomplished either by circumferential or antral ablation. At the end of the ablation procedure in both groups, AF or atrial flutter induction is attempted by isoproterenol infusion and high left atrial pacing. Induction of atrial fibrillation is registered but does not necessitate additional ablation. Induction of right, isthmus-dependent atrial flutter is dealt with cavotricuspid isthmus ablation. Left atrial flutters will be studied by means of entrainment from the mitral isthmus and the adjacent posterior wall. Since a considerable percentage of these arrhythmias disappear with time,20 they will be ablated only if sustained (> 3 minutes) and associated with 1:1 ventricular response. Follow-up. Patients will be prospectively assessed for recurrence of AF or other atrial arrhythmia. As part of our routine AF ablation protocol, all patients are receiving beta blockers, whereas all patients are kept on amiodarone and warfarin for 3 months post-ablation. Patients will be subjected to monthly clinical assessment and ambulatory electrocardiographic monitoring for 2 years. All patients are instructed to maintain personal records with descriptions of every episode of symptomatic palpitations and, in case of persistent arrhythmia episodes, to obtain trans-telephonic or electrocardiographic documentation of the underlying rhythm. Patients will be encouraged to use trans-telephonic monitoring even when their symptoms are not typical for recurrent AF. A successful outcome over the follow-up period is defined as the lack of electrocardiographically recorded AF, and no AF or other atrial arrhythmia on Holter, and subjective symptomatic improvement after a 3-month blanking period. Heart rate variability will be measured at 6, 12, 18 and 24 months after ablation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation
Keywords
atrial fibrillation, PV isolation, ablation, ganglionic plexi, parasympathetic denervation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Circumferential PV isolation
Arm Title
2
Arm Type
Active Comparator
Arm Description
HF stimulation-guided and anatomic ablation of the main right and left atrial GP.
Arm Title
3
Arm Type
Active Comparator
Arm Description
HF stimulation-guided and anatomic ablation of the main right and left atrial GP followed by circumferential PV isolation
Intervention Type
Procedure
Intervention Name(s)
GP ablation
Intervention Description
HF stimulation-guided and anatomic ablation of the main right and left atrial GP
Intervention Type
Procedure
Intervention Name(s)
PV isolation
Intervention Description
Circumferential PV isolation
Primary Outcome Measure Information:
Title
Freedom of AF or other atrial arrhythmia
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Quality of life
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: paroxysmal AF age < 75 years left atrial size < 5 cm Exclusion Criteria: malignancies LVEF < 35%
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
D Katritsis, MD
Organizational Affiliation
Cardiovascular Research Society
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
E Pokushalov, MD
Organizational Affiliation
State Research Institute of Circulation Pathology, Novosibirsk, Russia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Athens Euroclinic
City
Athens
ZIP/Postal Code
11521
Country
Greece
Facility Name
State Research Institute of Circulation Pathology
City
Novosibirsk
Country
Russian Federation

12. IPD Sharing Statement

Citations:
PubMed Identifier
16923757
Citation
Scanavacca M, Pisani CF, Hachul D, Lara S, Hardy C, Darrieux F, Trombetta I, Negrao CE, Sosa E. Selective atrial vagal denervation guided by evoked vagal reflex to treat patients with paroxysmal atrial fibrillation. Circulation. 2006 Aug 29;114(9):876-85. doi: 10.1161/CIRCULATIONAHA.106.633560. Epub 2006 Aug 21.
Results Reference
background
PubMed Identifier
11094046
Citation
Schauerte P, Scherlag BJ, Pitha J, Scherlag MA, Reynolds D, Lazzara R, Jackman WM. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation. 2000 Nov 28;102(22):2774-80. doi: 10.1161/01.cir.102.22.2774.
Results Reference
background
PubMed Identifier
18195170
Citation
Lemola K, Chartier D, Yeh YH, Dubuc M, Cartier R, Armour A, Ting M, Sakabe M, Shiroshita-Takeshita A, Comtois P, Nattel S. Pulmonary vein region ablation in experimental vagal atrial fibrillation: role of pulmonary veins versus autonomic ganglia. Circulation. 2008 Jan 29;117(4):470-7. doi: 10.1161/CIRCULATIONAHA.107.737023. Epub 2008 Jan 14.
Results Reference
background
PubMed Identifier
17919294
Citation
McClelland JH, Duke D, Reddy R. Preliminary results of a limited thoracotomy: new approach to treat atrial fibrillation. J Cardiovasc Electrophysiol. 2007 Dec;18(12):1289-95. doi: 10.1111/j.1540-8167.2007.00977.x. Epub 2007 Oct 5.
Results Reference
background
PubMed Identifier
12716107
Citation
Nakagawa H, Jackman WM, Scherlag BJ, Lazzara R. Pulmonary vein isolation during atrial fibrillation: insight into the mechanism of pulmonary vein firing. J Cardiovasc Electrophysiol. 2003 Mar;14(3):261-2. doi: 10.1046/j.1540-8167.2003.03002.x. No abstract available.
Results Reference
background
PubMed Identifier
14707026
Citation
Pappone C, Santinelli V, Manguso F, Vicedomini G, Gugliotta F, Augello G, Mazzone P, Tortoriello V, Landoni G, Zangrillo A, Lang C, Tomita T, Mesas C, Mastella E, Alfieri O. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation. 2004 Jan 27;109(3):327-34. doi: 10.1161/01.CIR.0000112641.16340.C7. Epub 2004 Jan 5.
Results Reference
background
PubMed Identifier
16731474
Citation
Oh S, Zhang Y, Bibevski S, Marrouche NF, Natale A, Mazgalev TN. Vagal denervation and atrial fibrillation inducibility: epicardial fat pad ablation does not have long-term effects. Heart Rhythm. 2006 Jun;3(6):701-8. doi: 10.1016/j.hrthm.2006.02.020. Epub 2006 Mar 6.
Results Reference
background
PubMed Identifier
12521345
Citation
Hirose M, Leatmanoratn Z, Laurita KR, Carlson MD. Partial vagal denervation increases vulnerability to vagally induced atrial fibrillation. J Cardiovasc Electrophysiol. 2002 Dec;13(12):1272-9. doi: 10.1046/j.1540-8167.2002.01272.x.
Results Reference
background
PubMed Identifier
15028356
Citation
Cummings JE, Gill I, Akhrass R, Dery M, Biblo LA, Quan KJ. Preservation of the anterior fat pad paradoxically decreases the incidence of postoperative atrial fibrillation in humans. J Am Coll Cardiol. 2004 Mar 17;43(6):994-1000. doi: 10.1016/j.jacc.2003.07.055.
Results Reference
background
PubMed Identifier
18515667
Citation
Pokushalov E, Turov A, Shugayev P, Artyomenko S, Romanov A, Shirokova N. Catheter ablation of left atrial ganglionated plexi for atrial fibrillation. Asian Cardiovasc Thorac Ann. 2008 Jun;16(3):194-201. doi: 10.1177/021849230801600304.
Results Reference
background
PubMed Identifier
18638596
Citation
Katritsis D, Giazitzoglou E, Sougiannis D, Goumas N, Paxinos G, Camm AJ. Anatomic approach for ganglionic plexi ablation in patients with paroxysmal atrial fibrillation. Am J Cardiol. 2008 Aug 1;102(3):330-4. doi: 10.1016/j.amjcard.2008.03.062. Epub 2008 May 22.
Results Reference
background
PubMed Identifier
23973694
Citation
Katritsis DG, Pokushalov E, Romanov A, Giazitzoglou E, Siontis GC, Po SS, Camm AJ, Ioannidis JP. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol. 2013 Dec 17;62(24):2318-25. doi: 10.1016/j.jacc.2013.06.053. Epub 2013 Aug 21.
Results Reference
derived
PubMed Identifier
21199686
Citation
Katritsis DG, Giazitzoglou E, Zografos T, Pokushalov E, Po SS, Camm AJ. Rapid pulmonary vein isolation combined with autonomic ganglia modification: a randomized study. Heart Rhythm. 2011 May;8(5):672-8. doi: 10.1016/j.hrthm.2010.12.047. Epub 2010 Dec 31.
Results Reference
derived

Learn more about this trial

Circumferential Versus Ganglionated Plexi Ablation for Atrial Fibrillation (AF)

We'll reach out to this number within 24 hrs